At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
News|Articles|February 22, 2023
FDA Recommends Recall of Artificial Eye Ointment for Potential Bacterial Contamination
Author(s)Pharmaceutical Technology Editors
This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
Advertisement
FDA is warning consumers and health care professionals of the use of Delsam Pharma’s Artificial Eye Ointment because of potential bacterial contamination. This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
These over-the-counter products are manufactured by Global Pharma Healthcare Private Limited and are intended to be sterile. The use of the ointment can increase the risk of eye infections that can result in blindness according to FDA, and patients who have signs or symptoms of an eye infection should talk to their health care provider or seek medical care immediately warns the agency. FDA recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment on February 22, 2023.
Source:
Advertisement
Related to this article
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Advertisement
Advertisement